HOME >> BIOLOGY >> NEWS
Treatments for urinary infections leave bacteria bald, happy and vulnerable

enetic mutation that allows it to survive," Pinkner explains. "We think that pilicides will greatly reduce the pressure to develop resistance and have already shown in the lab that they have no effect on E. coli's growth or metabolic state."

Pinkner notes that all Gram-negative bacteria, including Yersinia pesitis (plague), Salmonella, and Klebsiella pneumoniae (pneumonia and burn and urinary tract infections) make pili and may be susceptible to the same treatments. Keeping the target of the drug specifically aimed at a virulence factor not essential for growth reduces the chances for general resistance to spread, Pinkner asserts. He also notes that such drugs will have fewer effects on bacteria that benefit the host by contributing to healthy human physiology.

"For example, there are bacteria in the intestinal tract that aid in metabolism and the normal function of the intestine, which also helps prevent this niche from being occupied by pathogenic bacteria," he explains. "Given the rise in antibiotic resistance, it is critical to design antimicrobials for the future that target the bad bacteria but leave the good ones alone."


'"/>

Contact: Michael Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
20-Dec-2006


Page: 1 2 3

Related biology news :

1. Treatments have same target, different responses for lung cancer patients with genetic mutation
2. Attack is the best defence against urinary tract infection
3. Injecting stem cells from a womans own muscle may effectively treat urinary incontinence
4. Study demonstrates rapid diagnosis of urinary tract infections with biosensor technology
5. Progress toward a new remedy for chronic urinary tract infections?
6. UCSB researchers advance understanding of urinary tract infections
7. Bugs-eye-view of urinary tract reveals E.coli infection genes
8. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate
9. Injection drug use and HIV and HCV infections among Ontario prison inmates
10. Injection drug use the most important risk factor for HIV and HCV infections among Quebec prisoners
11. Mucins stand guard against gut infections

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) today ... of up to $250 million of the company,s common ... remain open through December 31, 2017. Purchases may be ... in privately negotiated transactions from time to time as ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead Publishers is pleased to ... coming to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, ... advances in the treatment of various types of pain. There are also extended ...
(Date:4/27/2017)... ... April 27, 2017 , ... The ... Communication Award goes to Jayson Lusk, a consummate communicator who promotes agricultural science ... advocate for science, as he explains how innovation and growth in agriculture are ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ... I clinical trials comes to Tampa, San Francisco and Boston in 2017. ... FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix ...
Breaking Biology Technology:
Cached News: